Risperdal Consta (Johnson & Johnson) contains risperidone, an atypical antipsychotic that acts as a selective dopamine and serotonin receptor antagonist that also blocks the dopamine D2, serotonin (5-HT2), and alpha-2 adrenergic receptors. Risperdal Consta is the long-acting injectable formulation of Johnson & Johnson’s oral drug Risperdal.
Risperdal was initially approved for bipolar disorder in the US in 2003. Johnson & Johnson later launched Risperdal Consta in the US in May 2009. In the following year, EU regulators denied Risperdal Consta approval for the treatment of bipolar disorder, which prompted Johnson & Johnson to abandon the development program in these markets. The drug is also approved for the treatment of schizophrenia.
LIST OF FIGURES
11 Figure 1: Risperdal Consta for bipolar disorder – SWOT analysis
12 Figure 2: Datamonitor Healthcare’s drug assessment summary for Risperdal Consta in bipolar disorder
13 Figure 3: Datamonitor Healthcare’s drug assessment summary for Risperdal Consta in bipolar disorder
19 Figure 4: Risperdal Consta for schizophrenia – SWOT analysis
20 Figure 5: Datamonitor Healthcare’s drug assessment summary of Risperdal Consta for schizophrenia
21 Figure 6: Datamonitor Healthcare’s drug assessment summary of Risperdal Consta for schizophrenia
23 Figure 7: Risperdal Consta sales for schizophrenia across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Risperdal Consta bipolar disorder indication approvals
6 Table 2: Risperdal Consta drug profile
8 Table 3: Risperdal Consta pivotal trial data in bipolar disorder
10 Table 4: Adverse reactions in ≥5% of Risperdal Consta-treated adult patients with bipolar disorder
16 Table 5: Risperdal Consta drug profile
18 Table 6: Risperdal Consta pivotal trial data in schizophrenia
24 Table 7: Risperdal Consta sales for schizophrenia across the US, Japan, and five major EU markets, by country ($m), 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.